Founded on the September 18th, 2017 and headquartered near Düsseldorf, Germany, Priavoid GmbH is a pharmaceutical company focused on the development of innovative disease-modifying therapies for patients with severe neurological disorders. Priavoid’s pharmaceutical development programs are exclusively based on D-enantiomeric peptides (all-D-peptides).
The most advanced drug in our pipeline is named PRI-002. The orally available clinical stage drug candidate directly eliminates toxic amyloid-beta (Aß) oligomers for the causal treatment of Alzheimer’s disease (AD). Oral administration resulted in significantly improved cognitive read out in three different in vivo models.
The First-in-Human phase I single ascending dose (SAD) and the multiple ascending dose (MAD) clinical trials with PRI-002 were successfully completed, demonstrating excellent safety, tolerability and pharmacokinetic profiles. The MAD part included administration of PRI-002 up to 320 mg/subject/day orally for 28 days to healthy volunteers.
Priavoid’s development pipeline is targeting additional orphan and non-orphan CNS disorders caused by misfolded peptides, incl. tauopathies and Parkinson’s disease (PD).